Pharmacovigilance Market Outlook 2025–2029: Emerging Opportunities and Key Drivers

Uncover key drivers, emerging technologies, and competitive movements shaping the pharmacovigilance market from 2025–2034 with trusted insights from The Business Research Company

What Is The Present Size Of The Pharmacovigilance Market And What Value Is Projected For 2029?

The pharmacovigilance market has experienced swift expansion in recent years. It is projected to increase from $8.58 billion in 2024 to $9.64 billion in 2025, achieving a compound annual growth rate (CAGR) of 12.4%. This historical growth can be attributed to the increasing incidence of adverse drug reactions (ADRs), heightened research and development (R&D) activities, growing drug development rates, an increasing focus on personalized medicine, and the rising prevalence of chronic diseases.

The pharmacovigilance market is projected to experience swift expansion over the coming years. This market is anticipated to reach $15.5 billion by 2029, achieving a compound annual growth rate (CAGR) of 12.6%. Factors contributing to this growth during the forecast period include increasing healthcare spending, greater governmental backing, and the expanding elderly demographic. Key trends identified for this period encompass heightened investments, the adoption of artificial intelligence, the utilization of cutting-edge platforms, the deployment of innovative cloud-based systems, and strategic consolidations and acquisitions.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5928&type=smp

What Factors Are Boosting The Pharmacovigilance Market?

Elevated levels of research and development endeavors are projected to propel the pharmacovigilance market forward. Through capital injection into R&D, pharmaceutical firms are empowered to create novel and cutting-edge medications featuring enhanced safety characteristics. Thorough preclinical and clinical assessments conducted throughout drug formulation facilitate the prompt detection of possible safety issues, thereby enabling the deployment of suitable risk reduction measures. Furthermore, R&D initiatives contribute to progress in adverse event surveillance technologies, data interpretation, and signal identification, which aids in the swift discovery of adverse drug reactions following market release. As an illustration, in February 2024, data from the Llywodraeth Cymru Welsh Government, a UK-based governmental body, indicated that in 2022, Wales channeled £1.0 billion ($1.25 billion) into Business Expenditure on Research and Development (BERD), representing 1.9% of the collective UK spending in this sector. Consequently, the rise in research and development operations has underpinned the expansion of the pharmacovigilance market.

What Are The Core Segmentation Criteria In The Pharmacovigilance Market?

The pharmacovigilance market covered in this report is segmented –

1) By Type: Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining

2) By Service Provider: In-House, Contract Outsourcing

3) By Process Flow: Case Data Management, Signal Detection, Risk Management System

4) By Clinical Trial Phases: Preclinical, Phase I, Phase II, Phase III, Phase IV

5) By End User: Hospitals, Pharmaceutical Companies, Other End Users

Subsegments:

1) By Spontaneous Reporting: Individual Case Safety Reports (ICSRs), Voluntary Reporting Systems, Case Reports From Healthcare Professionals

2) By Intensified ADR Reporting: Active Surveillance Programs, Enhanced Monitoring In Clinical Trials, Risk Minimization Strategies

3) By Targeted Spontaneous Reporting: Reporting For Specific Drug Classes, Condition-Specific Reporting, Focused Surveillance Programs

4) By Cohort Event Monitoring: Prospective Cohort Studies, Retrospective Cohort Studies, Longitudinal Studies

5) By EHR Mining: Data Extraction From Electronic Health Records, Signal Detection Through EHR Analysis, Integration Of EHR Data With Pharmacovigilance Systems

Which Emerging Trends Are Reshaping The Pharmacovigilance Market Landscape?

Companies operating within the pharmacovigilance market are increasingly leveraging artificial intelligence (AI) to boost their operational effectiveness. AI is instrumental in enhancing both the efficiency and accuracy of pharmacovigilance processes, ultimately leading to improved patient outcomes. By deploying AI, pharmaceutical enterprises can streamline their workflows, optimize data management, and accelerate drug discovery, concurrently reducing costs and elevating safety standards. As an illustration, in August 2024, the Government of India introduced the Adverse Drug Reaction Monitoring System (ADRMS) software, launched by the Minister of Health & Family Welfare and Minister of Chemicals and Fertilizers. This pharmacovigilance software simplifies the collection and analysis of adverse events associated with medicines and medical devices, making the reporting procedure more accessible for both consumers and healthcare professionals. This endeavor significantly fortifies India’s pharmacovigilance infrastructure by ensuring a more comprehensive capture of safety data and augmenting drug safety monitoring. The ADRMS aims to enhance the efficacy of drug safety oversight and compliance with established standards, thereby contributing to India’s position as a leader in the global pharmaceutical industry.

Which Players Are Shaping The Competitive Landscape Of The PharmacovigilanceXX Market?

Major companies operating in the pharmacovigilance market include IQVIA, Cognizant, ICON Plc, Accenture plc, PAREXEL International Corporation., United BioSource LLC, ArisGlobal, Quanticate, Wipro Limited, Linical Americas, Novotech CRO, Wuxi Apptec, Simcere Pharmaceutical Group, Lee’s Pharmaceutical Holdings, Luye Pharma Group, EXTEDO, Arriello, PrimeVigilance, Axios International, C3i Solutions, Alcon, Secure AI Labs, OmniSol dot Tech, Canna Call Company, Veripad, Prevnos Inc., Lifescient, Inc, BeiGene, QuintilesIMS, Labcorp Drug Development, Pharmaceutical Product Development Inc., PRA Health Sciences, Synowledge LLC, RAPAhub, illuminate health, Invenio Medical, ClinChoice Inc., MSD, Novasyte, Fortrea Holdings Inc, Syneos Health Clinical, Zoetis Inc., Telerx Marketing Inc., Gilead Sciences, Inc., Elanco, Abbott Laboratories, Spimaco, Teva Pharmaceutical Industries Ltd.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pharmacovigilance-global-market-report

What Regional Trends Are Shaping Growth In The Pharmacovigilance Market?

North America was the largest region in the pharmacovigilance market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast region. The regions covered in the pharmacovigilance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=5928&type=smp

Browse Through More Reports Similar to the Global Pharmacovigilance Market 2025, By The Business Research Company

Pharmaceutical Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharmaceutical-drugs-global-market-report

Pharmaceutical Excipient Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharmaceutical-excipient-global-market-report

Pharma Microbiology Testing Kits Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharma-microbiology-testing-kits-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795